Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12646193 | 0.84 | CLK4 (0.39) | — | |
| SCHEMBL394338 | 0.83 | PRMT5 (0.37) | PDE3BPDE3AMTORCYP11B1CYP11B2 | |
| SCHEMBL328270 | 0.82 | DAPK3 (0.38) | — | |
| SCHEMBL12049915 | 0.78 | AHR (0.42) | PDE3BPDE3ACYP11B1CYP11B2 | |
| SCHEMBL13348258 | 0.77 | PPOX (0.37) | — | |
| SCHEMBL14792947 | 0.77 | PDE3B (0.39) | PDE3BPDE3ACYP11B1CYP11B2 | |
| SCHEMBL14114009 | 0.76 | EIF2AK2 (0.44) | PDE3BPDE3ACYP11B1CYP11B2 | |
| SCHEMBL13266843 | 0.74 | MMP12 (0.50) | PDE3BPDE3A | |
| SCHEMBL12094128 | 0.72 | NPC1 (0.31) | — | |
| SCHEMBL10224843 | 0.72 | PBRM1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902189-B2 | antitumor agent, anticarcinogenic agents; 7-Chloro-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine; inhibitors of mTOR kinase | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-20080081809-A1 | Novel Compounds | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081809-A1 | Novel Compounds | SLC10A1, ABCB11, PKD1 | PDE3B 1357/4885PDE3A 1649/4885MTOR 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.